Lugar de publicación
- Active immunization of cattle with a bothropic toxoid does not abrogate envenomation by Bothrops asper venom, but increases the likelihood of survival. 46:1-5. 2017
- Purification of equine whole IgG snake antivenom by using an aqueous two phase system as a primary purification step. 43:37-46. 2015
- Assessment of snake antivenom purity by comparing physicochemical and immunochemical methods. 41:93-97. 2013
- Low pH formulation of whole IgG antivenom: Impact on quality, safety, neutralizing potency and viral inactivation. 40:129-133. 2012
- Antivenoms for the treatment of snakebite envenomings: The road ahead. 39:129-142. 2011
- Intravenous administration of equine-derived whole IgG antivenom does not induce early adverse reactions in non-envenomed horses and cows. 38:664-669. 2010
- Study of the design and analytical properties of the lethality neutralization assay used to estimate antivenom potency against Bothrops asper snake venom. 38:577-585. 2010
- Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom. 37:306-312. 2009
- Development and validation of a reverse phase HPLC method for the determination of caprylic acid in formulations of therapeutic immunoglobulins and its application to antivenom production. 37:230-234. 2009
- Anti-human erythrocyte antibodies in horse-derived antivenoms used in the treatment of snakebite envenomations. 35:5-11. 2007
- Assessment of the viral safety of antivenoms fractionated from equine plasma. 32:115-128. 2004
- Effect of preservatives on IgG aggregation, complement-activating effect and hypotensive activity of horse polyvalent antivenom used in snakebite envenomation. 30:143-151. 2002